Currently, the only biomarker approved to guide the prescription of ICIs in different NSCLC clinical scenarios is the tumor-proportional score (TPS) of PD-L1 in the tumor, despite its limited predictive value [7,8,9,10]. The gene discussed is CD274; the disease is neoplasm.